Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.34
ILMN's Cash to Debt is ranked higher than
68% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ILMN: 1.34 )
ILMN' s 10-Year Cash to Debt Range
Min: 0.97   Max: 16544
Current: 1.34

0.97
16544
Equity to Asset 0.51
ILMN's Equity to Asset is ranked higher than
60% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ILMN: 0.51 )
ILMN' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.95
Current: 0.51

0.42
0.95
Interest Coverage 3.38
ILMN's Interest Coverage is ranked lower than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ILMN: 3.38 )
ILMN' s 10-Year Interest Coverage Range
Min: 3.38   Max: 9999.99
Current: 3.38

3.38
9999.99
F-Score: 5
Z-Score: 8.21
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.44
ILMN's Operating margin (%) is ranked higher than
74% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. ILMN: 9.44 )
ILMN' s 10-Year Operating margin (%) Range
Min: -1775.02   Max: 23.45
Current: 9.44

-1775.02
23.45
Net-margin (%) 8.82
ILMN's Net-margin (%) is ranked higher than
77% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. ILMN: 8.82 )
ILMN' s 10-Year Net-margin (%) Range
Min: -1421.39   Max: 21.65
Current: 8.82

-1421.39
21.65
ROE (%) 8.17
ILMN's ROE (%) is ranked higher than
74% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ILMN: 8.17 )
ILMN' s 10-Year ROE (%) Range
Min: -67.62   Max: 16.16
Current: 8.17

-67.62
16.16
ROA (%) 4.15
ILMN's ROA (%) is ranked higher than
73% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. ILMN: 4.15 )
ILMN' s 10-Year ROA (%) Range
Min: -33.08   Max: 13.3
Current: 4.15

-33.08
13.3
ROC (Joel Greenblatt) (%) 37.06
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. ILMN: 37.06 )
ILMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2033.68   Max: 78.08
Current: 37.06

-2033.68
78.08
Revenue Growth (%) 17.30
ILMN's Revenue Growth (%) is ranked higher than
91% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ILMN: 17.30 )
ILMN' s 10-Year Revenue Growth (%) Range
Min: -2   Max: 160.9
Current: 17.3

-2
160.9
EBITDA Growth (%) 6.40
ILMN's EBITDA Growth (%) is ranked higher than
73% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. ILMN: 6.40 )
ILMN' s 10-Year EBITDA Growth (%) Range
Min: -70.3   Max: 529.1
Current: 6.4

-70.3
529.1
EPS Growth (%) 1.10
ILMN's EPS Growth (%) is ranked higher than
71% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. ILMN: 1.10 )
ILMN' s 10-Year EPS Growth (%) Range
Min: -40.2   Max: 205.7
Current: 1.1

-40.2
205.7
» ILMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ILMN Guru Trades in Q1 2013

Vanguard Health Care Fund 2,240,200 sh (New)
Pioneer Investments 46,300 sh (New)
George Soros 40,000 sh (New)
Andreas Halvorsen 200,500 sh (New)
Mario Gabelli 32,700 sh (+14.74%)
PRIMECAP Management 2,076,200 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
John Burbank Sold Out
Daniel Loeb Sold Out
Ron Baron 1,216,322 sh (-2.13%)
Steven Cohen 349,414 sh (-18.74%)
John Hussman 400,000 sh (-60%)
Louis Moore Bacon 50,000 sh (-64.29%)
» More
Q2 2013

ILMN Guru Trades in Q2 2013

Paul Tudor Jones 3,100 sh (New)
Pioneer Investments 94,000 sh (+103.02%)
Ron Baron 2,164,898 sh (+77.99%)
Jean-Marie Eveillard 400 sh (unchged)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Andreas Halvorsen Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,028,200 sh (-2.31%)
Mario Gabelli 24,500 sh (-25.08%)
George Soros 25,000 sh (-37.5%)
» More
Q3 2013

ILMN Guru Trades in Q3 2013

Jim Simons 164,718 sh (New)
Steven Cohen 3,050 sh (New)
Stanley Druckenmiller 506,700 sh (New)
Ron Baron 2,216,345 sh (+2.38%)
PRIMECAP Management 2,035,663 sh (+0.37%)
Paul Tudor Jones 3,100 sh (unchged)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Pioneer Investments 86,127 sh (-8.38%)
Mario Gabelli 18,500 sh (-24.49%)
George Soros 10,102 sh (-59.59%)
» More
Q4 2013

ILMN Guru Trades in Q4 2013

Andreas Halvorsen 1,696,962 sh (New)
PRIMECAP Management 2,048,063 sh (+0.61%)
Vanguard Health Care Fund 2,240,200 sh (unchged)
Paul Tudor Jones 3,100 sh (unchged)
George Soros 10,102 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Stanley Druckenmiller 506,700 sh (unchged)
Steven Cohen Sold Out
Ron Baron 2,209,790 sh (-0.3%)
Mario Gabelli 16,500 sh (-10.81%)
Pioneer Investments 61,619 sh (-28.46%)
Jim Simons 44,618 sh (-72.91%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Reduce -59.59%0.01%$73.36 - $85.34 $ 136.2273%10102
Mario Gabelli 2013-09-30 Reduce -24.49%$73.36 - $85.34 $ 136.2273%18500
John Hussman 2013-06-30 Sold Out 0.79%$54.24 - $74.95 $ 136.22107%0
Ron Baron 2013-06-30 Add 77.99%0.37%$54.24 - $74.95 $ 136.22107%2164898
George Soros 2013-06-30 Reduce -37.5%0.01%$54.24 - $74.95 $ 136.22107%25000
Mario Gabelli 2013-06-30 Reduce -25.08%$54.24 - $74.95 $ 136.22107%24500
Daniel Loeb 2013-03-31 Sold Out 1.5%$48.36 - $55.59 $ 136.22163%0
John Hussman 2013-03-31 Reduce -60%0.9%$48.36 - $55.59 $ 136.22163%400000
Vanguard Health Care Fund 2013-03-31 New Buy0.48%$48.36 - $55.59 $ 136.22163%2240200
George Soros 2013-03-31 New Buy0.03%$48.36 - $55.59 $ 136.22163%40000
John Burbank 2013-03-31 Sold Out 0.01%$48.36 - $55.59 $ 136.22163%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Illumina, Inc.

Baron Funds Comments on Illumina Inc. - Aug 08, 2013

Shares of Illumina, Inc. (ILMN) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman)

From Ron Baron’s second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 02, 2013

Illumina, Inc. (ILMN) is the leading manufacturer of instruments and consumables used by scientists engaged in researching applications for 'next generation' DNA sequencing. Illumina's products have been at the forefront of huge recent advances in technology that have brought the cost of sequencing a human genome from roughly $1 billion 23 years ago, when the Human Genome Project was launched, to $3,000 today (and still declining rapidly). The company reported quarterly revenue and earnings growth ahead of Wall Street estimates, driven by strength across its entire product portfolio.We believe these results were driven by both growing end markets and market share gains, which may have accelerated after the company's main competitor announced it was considering selling itself.

From the Baron Funds’ second quarter 2013 commentary.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 01, 2013

Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis.

From Baron Funds’ first quarter 2013 letter.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - Aug 23, 2012

From Baron Funds' second quarter commentary:

We purchased shares of Illumina, Inc. (ILMN), a leading provider of tools and services for advanced genetic analysis. We have been following the company for several years, and we have long admired its business model and management team. During the quarter, we had an opportunity to buy Illumina's shares at a price we believed to be favorable. Roche Holding Ltd., a large Swiss-based pharmaceutical and biotech company, walked away from its hostile bid for Illumina, and Illumina's share price fell.

Illumina is the recognized leader in next generation DNA sequencing, a fast growing market with enormous potential. Until recently, DNA sequencing has been primarily used for research purposes. In the research market, Illumina's technology is the gold standard with approximately 90% of the world's DNA sequencing output currently produced on Illumina's instruments. As a result of rapid advances in technology, the cost of sequencing has declined dramatically over the past decade, and it is expected to fall to $1,000 per human genome in the near future. As the cost of sequencing declines, new applications for DNA sequencing are emerging. For example, sequencing is being used in cancer diagnosis and treatment. In some cases, a physician treating a cancer patient may have the patient's cancer tumor sequenced and may prescribe drugs that target mutations specific to the patient's cancer.

Illumina's sequencing platforms have been adopted by some well-known diagnostic reference labs, and Illumina is partnering with other labs to develop diagnostic kits. Illumina is conducting research and development on proprietary cancer diagnostic panels, initially focused on ovarian, gastric and colorectal cancers. In the future, Illumina management believes that infants will be sequenced at birth and their genetic profile will be used to manage their health throughout their lifetimes. Other market opportunities for Illumina include agricultural biology, veterinary medicine and forensics. Combined, we believe that these new markets have the potential to more than double the size of Illumina's addressable market from $4 billion to over $8 billion.

Although Illumina faces competition, and technology in this field is advancing at a rapid pace, Illumina has a proven track record of innovating, and we believe it will remain a technology leader. Illumina spends a significantly higher percentage of its revenue on research and development than its peers. The management team is highly regarded in the industry and we think has attracted some of the best talent in the field.

Illumina's business comprises an attractive "razor/blade model" in which the company sells instruments and then generates recurring revenue from consumables used with those instruments. The company generates high profit margins, which we think will expand over time as the company's revenue mix shifts to a higher percentage of high-margin consumable revenue generated from its installed instrument base. Illumina has a strong balance sheet, which provides management financial flexibility to re-invest in its business, repurchase shares or acquire new technologies.


Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina, Inc.

Baron Funds Comments on Illumina Inc.
Shares of Illumina, Inc. (ILMN) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (ILMN) is the leading manufacturer of instruments and consumables used by scientists engaged in researching applications for 'next generation' DNA sequencing. Illumina's products have been at the forefront of huge recent advances in technology that have brought the cost of sequencing a human genome from roughly $1 billion 23 years ago, when the Human Genome Project was launched, to $3,000 today (and still declining rapidly). The company reported quarterly revenue and earnings growth ahead of Wall Street estimates, driven by strength across its entire product portfolio.We believe these results were driven by both growing end markets and market share gains, which may have accelerated after the company's main competitor announced it was considering selling itself. Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 158.20
ILMN's P/E(ttm) is ranked lower than
68% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.10 vs. ILMN: 158.20 )
ILMN' s 10-Year P/E(ttm) Range
Min: 34.32   Max: 344.72
Current: 158.2

34.32
344.72
P/B 11.20
ILMN's P/B is ranked lower than
73% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ILMN: 11.20 )
ILMN' s 10-Year P/B Range
Min: 1.58   Max: 16.82
Current: 11.2

1.58
16.82
P/S 13.40
ILMN's P/S is ranked lower than
85% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. ILMN: 13.40 )
ILMN' s 10-Year P/S Range
Min: 3.4   Max: 17.02
Current: 13.4

3.4
17.02
PFCF 63.00
ILMN's PFCF is ranked lower than
66% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. ILMN: 63.00 )
ILMN' s 10-Year PFCF Range
Min: 13.32   Max: 138.5
Current: 63

13.32
138.5
EV-to-EBIT 125.00
ILMN's EV-to-EBIT is ranked lower than
73% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. ILMN: 125.00 )
ILMN' s 10-Year EV-to-EBIT Range
Min: 13.8   Max: 415.7
Current: 125

13.8
415.7
PEG 10.40
ILMN's PEG is ranked lower than
66% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.13 vs. ILMN: 10.40 )
ILMN' s 10-Year PEG Range
Min: 1.21   Max: 15.46
Current: 10.4

1.21
15.46
Shiller P/E 182.20
ILMN's Shiller P/E is ranked lower than
76% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. ILMN: 182.20 )
ILMN' s 10-Year Shiller P/E Range
Min: 84.23   Max: 1315.25
Current: 182.2

84.23
1315.25

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 35.90
ILMN's Price/Tangible Book is ranked lower than
94% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ILMN: 35.90 )
ILMN' s 10-Year Price/Tangible Book Range
Min: 1.55   Max: 29.18
Current: 35.9

1.55
29.18
Price/DCF (Projected) 4.90
ILMN's Price/DCF (Projected) is ranked lower than
76% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ILMN: 4.90 )
ILMN' s 10-Year Price/DCF (Projected) Range
Min: 1.53   Max: 18.18
Current: 4.9

1.53
18.18
Price/Median PS Value 1.70
ILMN's Price/Median PS Value is ranked lower than
61% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ILMN: 1.70 )
ILMN' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 20.59
Current: 1.7

0.51
20.59
Price/Peter Lynch Fair Value 11.90
ILMN's Price/Peter Lynch Fair Value is ranked lower than
92% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. ILMN: 11.90 )
ILMN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.73   Max: 9.68
Current: 11.9

1.73
9.68
Price/Graham Number 14.80
ILMN's Price/Graham Number is ranked lower than
86% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ILMN: 14.80 )
ILMN' s 10-Year Price/Graham Number Range
Min: 3.3   Max: 12.03
Current: 14.8

3.3
12.03
Earnings Yield (Greenblatt) 0.80
ILMN's Earnings Yield (Greenblatt) is ranked lower than
66% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ILMN: 0.80 )
ILMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 7.2
Current: 0.8

0.2
7.2
Forward Rate of Return (Yacktman) 14.15
ILMN's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ILMN: 14.15 )
ILMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4   Max: 37.7
Current: 14.15

-4
37.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:ILU.Germany
Illumina, Inc. was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company is a developer, manufacturer and marketer of integrated systems for the analysis of genetic variation and biological function. Using its proprietary technologies, it provides a line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and it expects to enter the market for molecular diagnostics. The Company's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. It develops and commercializes sequencing technologies used to perform a range of analyses, including de novo sequencing, whole genome re-sequencing, gene expression analysis and small RNA analysis. The Company's product and service offerings also include leading-edge solutions for single-nucleotide polymorphism genotyping, copy number variation, DNA methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Its tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to determine and analyze the billions of bits of genetic information needed to extract valuable medical information from advances in genomics and proteomics. During the first quarter of 2008, it reorganized its operating structure into two newly-created business segments, the Life Sciences Business Unit and the Diagnostics Business Unit. The Company's Life Sciences Business Unit includes all products and services that are mainly related to the research market, namely the product lines based on its sequencing, BeadArray, and VeraCode technologies, and its Diagnostics Business Unit focuses on the emerging opportunity in molecular diagnostics. It currently sells its products to a number of customers outside the United States, including customers in other areas of North America, Europe, and the Asia-Pacific region. The Company's manufacturing operations require a variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. The Company markets and distributes its products directly to customers in North America, Europe, and the Asia-Pacific region. The Company's main competiters are Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Complete Genomics, Inc.; General Electric Company; Helicos BioSciences Corporation; Life Technologies Corporation; Luminex Corporation; Pacific Biosciences, Inc.; Roche Diagnostics Corp.; Sequenom, Inc.; and Qiagen N.V. The Company's trademarks are Illumina(r), Array of Arraystm, BeadArraytm, BeadXpress(r), CSPro(r), DASL(r), Genetic Energytm, GoldenGate(r), GoldenGate Indexingtm, GenomeStudio(r), illuminaDxtm, HiSeqtm, Infinium(r), IntelliHyb(r), iSelect(r), Making Sense Out of Life(r), Oligator(r), Sentrix(r), Solexa(r) and VeraCode(r). The

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide